- bookmaker legit
- Published: 2025-01-09Source: bookmaker legit
Summary Tips: bookmaker legit is referred to as China News Service Guangxi Channel and China News Service Guangxi Network, which is the first news website established by the central media in Guangxi. bookmaker football Overall positioning: a comprehensive news website with external propaganda characteristics, the largest external communication platform in Guangxi. justbet bookmaker Provide services for industry enterprises, welcome to visit bookmaker legit !
Jones accounts for 4 TDs, defense adds two TDs, NC Central swamps Delaware State 52-10Giants Get Good Bill of Health vs. BucsMark Figley: Where do Democrats go from here?Robbie Williams and Nicole Scherzinger reportedly got in touch with Liam Payne's devastated family as they were unable to make his funeral
PDP governors call for unity, economic reforms, justice
Mysterious googly eyes go viral after appearing on public art in Oregon
Kirby Corp director William Waterman sells $5.2 million in stock
Pepper Pong, a portable game that combines elements of ping pong and pickleball, had done roughly $350,000 in sales as of last Friday afternoon, according to founder Tom Filippini. Twenty-four hours later, that figure had more than doubled — thanks to the company’s appearance that evening on ABC’s “Shark Tank.” “They were buying the connection more than the game,” he said. “You’re not giving a product. You’re giving a story about bringing people together. People are hungry for that connection.” Filippini pitched that story to the show’s “sharks,” talking about his struggles with alcoholism before getting sober in 2016. “We’ve easily gotten over 1,000 emails basically thanking us for telling our story, not for creating our product or asking about their order,” he said of the post-show response. “The product is really just a conduit in what we’re trying to accomplish, which is to head off this epidemic of isolation.” Filippini went on the show asking for $150,000 for a 10% stake in the company. He ultimately gave up 19 percent in exchange for an investment of that size from Todd Graves, founder of the Raising Cane’s fast food chain. It’s Pepper Pong’s first outside investment. Filippini said he’s put around $500,000 of his own money into the venture. Filippini noted that Graves is a paddle sports fan himself. He’s a part-owner of the Texas Ranchers, a professional pickleball team. And a Cane’s location built in collaboration with musician Post Malone has a pingpong track running along the walls of the restaurant. “I think Todd and I are really well-aligned in our feeling that business should be fun and lighthearted,” he said. “We call him the ‘aw-shucks’ billionaire.’” Filippini moved to Denver in 1997 and worked in mergers and acquisition investment before founding the vacation club Exclusive Resorts with Brent and Brad Handler in 2002. He sold the company, now based in McGregor Square, in 2004, and went back to the investing industry in 2010. In 2016, he started Aviation Innovation Holdings, a firm that invests in niche flight-industry companies. He spends nights and weekends, he said, on Pepper Pong. A self-proclaimed “ping pong fanatic,” Filippini grew up outside of Chicago playing table tennis with his two brothers and dad in their basement. “We’d play a lot and occasionally throw the rackets at each other and they’d break, so we’d be out of those for a while,” he said. This forced them to tinker with equipment, and led to them finding Nerf Ping Pong, the toy-gun empire’s tabletop version of the game. The ball was not up to snuff, he said, so they would source their own. Though they never found the perfect replacement, that idea became Pepper Pong decades later. “What we realized around 20 years ago is if you could soften the ball and slow the pace, you could level the playing field and extend rallies,” Filippini said. “You basically welcome more people to play and compete and have fun.” Pepper Pong retails on the company’s website for $70 a set, which includes four paddles, called “mullets,” and three foam balls, called “peppers.” The mullet has a ping pong base that shapes into more of a pickleball paddle on top. The peppers, about 30 percent bigger than a ping pong ball, are called jalapeño, habanero and ghost. They ascend in density and playability, with jalapeño being a beginner ball and ghost serving as the most difficult. The weight allows for more control and an approachable pace, Filippini said. Players can set up a “fence” — the game’s de facto net — anywhere from a car hood to Yeti cooler. This, he said, is a remedy to the space and equipment you need to play ping pong. The large table and speed that some people can hit the ball also makes a skill gap obvious, he said. Pepper Pong aims to level the playing field, and though there have been other portable ping pong sets on the market for decades that have tried to do the same thing, Filippini didn’t mince words when reflecting on their efficiency. “They’re a joke,” he said. Walmart and other retailers have reached out since the show to ask about carrying the product, Fillippini said, but he’s planning to sell on the Pepper Pong website for now, to ensure a deliberate roll out. “I was ready for that influx,” he said. “But we’re a zero full-time employee company, so we have to be very considerate about not biting off more than we can chew.” Pepper Pong is manufactured at a facility in Macao, China. Filippini noted it is the same center that produces Spikeball, another portable yard game. He was introduced to its founder, Chris Ruder, early on in the venture, and Filippini has sought advice from him throughout. Pepper Pong distributes out of a family-owned warehouse in Indiana. Filippini said he had to call on family and friends to help account for the massive order influx after the show.skynesher/E+ via Getty Images Mereo BioPharma Group Plc. ( NASDAQ: MREO ) has made significant progress in developing monoclonal antibody setrusumab with partner Ultragenyx Pharmaceutical Inc. ( RARE ) in the ongoing phase 3 ORBIT and COSMIC studies targeting This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year. Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
In a televised address to the country, the Russian president warned that U.S. air defense systems would be powerless to stop the new missile, which he said flies at ten times the speed of sound and which he called the Oreshnik — Russian for hazelnut tree. He also said it could be used to attack any Ukrainian ally whose missiles are used to attack Russia. “We believe that we have the right to use our weapons against military facilities of the countries that allow to use their weapons against our facilities,” Putin said in his first comments since President Joe Biden gave Ukraine the green light this month to use U.S. ATACMS missiles to strike at limited targets inside Russia. Pentagon deputy press secretary Sabrina Singh confirmed that Russia’s missile was a new, experimental type of intermediate range missile based on it’s RS-26 Rubezh intercontinental ballistic missile. “This was new type of lethal capability that was deployed on the battlefield, so that was certainly of concern," Singh said, noting that the U.S. was notified ahead of the launch through nuclear risk reduction channels. The attack on the central Ukrainian city of Dnipro came in response to Kyiv's use of longer-range U.S. and British missiles in strikes Tuesday and Wednesday on southern Russia, Putin said. Those strikes caused a fire at an ammunition depot in Russia's Bryansk region and killed and wounded some security services personnel in the Kursk region, he said. “In the event of an escalation of aggressive actions, we will respond decisively and in kind,” the Russian president said, adding that Western leaders who are hatching plans to use their forces against Moscow should “seriously think about this.” Putin said the Oreshnik fired Thursday struck a well-known missile factory in Dnipro. He also said Russia would issue advance warnings if it launches more strikes with the Oreshnik against Ukraine to allow civilians to evacuate to safety — something Moscow hasn’t done before previous aerial attacks. Kremlin spokesman Dmitry Peskov initially said Russia hadn’t warned the U.S. about the coming launch of the new missile, noting that it wasn't obligated to do so. But he later changed tack and said Moscow did issue a warning 30 minutes before the launch. Putin's announcement came hours after Ukraine claimed that Russia had used an intercontinental ballistic missile in the Dnipro attack, which wounded two people and damaged an industrial facility and rehabilitation center for people with disabilities, according to local officials. But American officials said an initial U.S. assessment indicated the strike was carried out with an intermediate-range ballistic missile. The attack comes during a week of escalating tensions , as the U.S. eased restrictions on Ukraine's use of American-made longer-range missiles inside Russia and Putin lowered the threshold for launching nuclear weapons. The Ukrainian air force said in a statement that the Dnipro attack was launched from Russia’s Astrakhan region, on the Caspian Sea. “Today, our crazy neighbor once again showed what he really is,” Ukrainian President Volodymyr Zelenskyy said hours before Putin's address. “And how afraid he is.” Russia was sending a message by attacking Ukraine with an intermediate-range ballistic missile capable of releasing multiple warheads at extremely high speeds, even if they are less accurate than cruise missiles or short-range ballistic missiles, said Matthew Savill, director of military sciences at the Royal United Services Institute, a London-based think tank. “Why might you use it therefore?” Savill said. "Signaling — signaling to the Ukrainians. We’ve got stuff that outrages you. But really signaling to the West ‘We’re happy to enter into a competition around intermediate range ballistic missiles. P.S.: These could be nuclear tipped. Do you really want to take that risk?’” Military experts say that modern ICBMs and IRBMs are extremely difficult to intercept, although Ukraine has previously claimed to have stopped some other weapons that Russia described as “unstoppable,” including the air-launched Kinzhal hypersonic missile. David Albright, of the Washington-based think tank the Institute for Science and International Security, said he was “skeptical” of Putin’s claim, adding that Russian technology sometimes “falls short.” He suggested Putin was “taunting the West to try to shoot it down ... like a braggart boasting, taunting his enemy.” Earlier this week, the Biden administration authorized Ukraine to use the U.S.-supplied, longer-range missiles to strike deeper inside Russia — a move that drew an angry response from Moscow. Days later, Ukraine fired several of the missiles into Russia, according to the Kremlin. The same day, Putin signed a new doctrine that allows for a potential nuclear response even to a conventional attack on Russia by any nation that is supported by a nuclear power. The doctrine is formulated broadly to avoid a firm commitment to use nuclear weapons. In response, Western countries, including the U.S., said Russia has used irresponsible nuclear rhetoric and behavior throughout the war to intimidate Ukraine and other nations. They have also expressed dismay at the deployment of thousands of North Korean troops to Russia to fight against Ukraine.) More than 1,000 days into war , Russia has the upper hand, with its larger army advancing in Donetsk and Ukrainian civilians suffering from relentless drone and missile strikes. Analysts and observers say the loosening of restrictions on Ukraine's use of Western missiles is unlikely to change the the course of the war, but it puts the Russian army in a more vulnerable position and could complicate the logistics that are crucial in warfare. Putin has also warned that the move would mean that Russia and NATO are at war. “It is an important move and it pulls against, undermines the narrative that Putin had been trying to establish that it was fine for Russia to rain down Iranian drones and North Korean missiles on Ukraine but a reckless escalation for Ukraine to use Western-supplied weapons at legitimate targets in Russia,” said Peter Ricketts, a former U.K. national security adviser who now sits in the House of Lords.After Trump's win, Black women are rethinking their role as America's reliable political organizersKawhi Leonard is close to returning for the Los Angeles Clippers. Zion Williamson and Brandon Ingram are further away from returning to the New Orleans Pelicans. Both teams will continue without key players when they meet Monday night in New Orleans. Leonard hasn't played this season because of knee inflammation, but he returned to practice more than a week ago and reportedly could play as soon as Jan. 4, though he won't be on the Clippers' three-game trip that begins in New Orleans. The Clippers also played without Terance Mann (finger), Kevin Porter Jr. (illness) and Kobe Brown (back) in their most recent game, a 102-92 home victory against Golden State on Friday. In the absence of the six-time All-Star, Los Angeles has compiled the fifth-best record in the Western Conference (tied with the crosstown Lakers). Head coach Tyronn Lue said believing that they can win without Leonard has been "half the battle." "When you step on the floor, no matter who's on the court, having that mindset that we can win games has been our model for the last five years or so," Lue said. "We talked about just holding it down until Kawhi was able to get back, and our group has been doing a good job of that." The Clippers had six double-figure scorers against Golden State, led by 26 points from Norman Powell, who has emerged as the team's leading scorer (24.2) in Leonard's absence. Center Ivica Zubac had his seventh straight double-double (17 points, 11 rebounds). They built a 21-point lead, watched the short-handed Warriors get within three with 2:30 left, then held on. Los Angeles committed 12 of its 23 turnovers in the fourth quarter. "It was a big win for us however you look at it," Lue said. "In three days, though, I won't remember how we won. I'll just know that it was a W." The Pelicans would be happy with any kind of win after losing their last nine games and 18 of their last 19. And no return date has been set for either of the team's top two players. Williamson has missed 26 games and Ingram has missed 14. New Orleans has not led in either of its last two games -- home losses against Memphis (132-124) on Friday and Houston (128-111) the night before. "(We have to) try to execute from the beginning, play hard from the beginning so we aren't always playing out of a hole," said forward Trey Murphy III, who led the Pelicans with a season-high 35 points against the Grizzlies. Murphy is averaging a career-best 20.2 points per game and he has averaged 26.2 in the last five games. He is New Orleans' most prolific 3-point shooter, but in the absence of Williamson and Ingram he has had to expand his scoring repertoire. "(Against Memphis) he played the right way the whole game," coach Willie Green said of Murphy. "When the ball came to him, he made good plays. He was solid, he shot the cover off the ball. He got to the basket, he got to the free-throw line. This is a great opportunity for Trey, and he took complete advantage of it." --Field Level Media
Trump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’Stock analysts at StockNews.com initiated coverage on shares of Moleculin Biotech ( NASDAQ:MBRX – Get Free Report ) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock. Separately, Maxim Group dropped their target price on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 12th. Get Our Latest Stock Analysis on Moleculin Biotech Moleculin Biotech Stock Performance Institutional Investors Weigh In On Moleculin Biotech A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC lifted its holdings in Moleculin Biotech, Inc. ( NASDAQ:MBRX – Free Report ) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the period. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock. Moleculin Biotech Company Profile ( Get Free Report ) Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. Further Reading Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter .Mysterious googly eyes go viral after appearing on public art in Oregon